Keyphrases
Prospective Randomized Trial
100%
Belatacept
100%
Immunosuppression
100%
Calcineurin Inhibitors
100%
Corticosteroids
100%
Randomized multicenter Trial
100%
Antithymocyte Globulin
78%
Tacrolimus
57%
Alemtuzumab
21%
Steroid Withdrawal
15%
Kidney Transplant
10%
Acute Rejection
10%
Biopsy Specimen
10%
Composite Endpoint
10%
Grafting Ratio
5%
Kidney Transplantation
5%
Maintenance Immunosuppression
5%
Calcineurin
5%
CD28
5%
T Cell Activation
5%
Randomized Clinical Trial
5%
Kidney Allograft Failure
5%
Neurological Effects
5%
Costimulation Blockade
5%
Immunosuppressive Therapy
5%
2-year Outcome
5%
Nephrotoxicity
5%
Multicenter Cohort Study
5%
Clinical Trial Registry
5%
Early Steroid Withdrawal
5%
Patient Survival Rate
5%
Gastrointestinal Side Effects
5%
Medicine and Dentistry
Immunosuppressive Treatment
100%
Calcineurin Inhibitor
100%
Belatacept
100%
Thymocyte Antibody
78%
Tacrolimus
57%
Alemtuzumab
21%
Kidney Graft
10%
Acute Graft Rejection
10%
Biopsy Sample
10%
T Cell
5%
Randomized Clinical Trial
5%
Clinical Trial
5%
Kidney Allograft
5%
Kidney Transplantation
5%
Adverse Event
5%
Graft Survival
5%
Survival Rate
5%
Nephrotoxicity
5%
Calcineurin
5%
Pharmacology, Toxicology and Pharmaceutical Science
Calcineurin Inhibitor
100%
Belatacept
100%
Leporidae
78%
Thymocyte Antibody
78%
Tacrolimus
57%
Alemtuzumab
21%
Acute Graft Rejection
10%
Clinical Trial
5%
Randomized Clinical Trial
5%
Nephrotoxicity
5%
Adverse Event
5%
Immunosuppressive Agent
5%
Survival Rate
5%
Calcineurin
5%
Immunology and Microbiology
Immunosuppression
100%
Belatacept
100%
Anti-Thymocyte Globulin
78%
Leporidae
78%
Tacrolimus
57%
Alemtuzumab
21%
Acute Graft Rejection
10%
Immunosuppressive Therapy
5%
CD28
5%
Survival Rate
5%
T Cell
5%
Kidney Transplantation
5%
Allograft
5%
Biochemistry, Genetics and Molecular Biology
Belatacept
100%
Calcineurin
100%
Leporidae
78%
Anti-Thymocyte Globulin
78%
Alemtuzumab
21%
Clinical Trial
5%
Randomized Clinical Trial
5%
CD28
5%
Survival Rate
5%
T Cell
5%